肝硬化肝肾综合征型急性肾损伤的诊治进展

宋廷雪; 祁兴顺; 高帆; 郭晓钟

doi:10.3969/j.issn.1001-5256.2017.03.039

肝硬化肝肾综合征型急性肾损伤的诊治进展

DOI: 10.3969/j.issn.1001-5256.2017.03.039

1. 辽宁中医药大学研究生院
2. 中国人民解放军沈阳军区总院消化内科
3. 解放军第二二医院医务处

详细信息

中图分类号: R575.2;R692.5
计量
- 文章访问数: 1936
- HTML全文浏览量: 8
- PDF下载量: 479
- 被引次数: 0
出版历程
- 收稿日期: 2016-10-14
- 出版日期: 2017-03-20

Advances in diagnosis and treatment of hepatorenal syndrome type of acute kidney injury in patients with liver cirrhosis

Graduate School of Liaoning University of Traditional Chinese Medicine

摘要

摘要: 急性肾损伤（AKI）是一种常见的肝硬化并发症,其主要表现为血肌酐迅速升高、肾小球滤过率降低、少尿或无尿。1型肝肾综合征（HRS-1）是AKI的一种特殊类型,未经治疗的HRS-1死亡风险极高,尽早诊断及治疗尤为重要。归纳了肝硬化AKI及HRS-AKI的最新诊断标准,并总结了有关HRS-1治疗的临床研究进展。
- 肝硬化 /
- 肝肾综合征 /
- 诊断 /
- 治疗 /
- 综述
Abstract: Acute kidney injury (AKI) is a common complication of liver cirrhosis and mainly manifests as a rapidly elevated serum creatinine level, a reduced glomerular filtration rate, and oliguria or anuria.Type 1 hepatorenal syndrome (HRS-1) is a special type of AKI, and patients with untreated HRS-1 have an extremely high risk of death.Early diagnosis and treatment are of great importance.This paper summarizes the latest diagnostic criteria for hepatorenal syndrome (HRS) type of AKI and research advances in the treatment of HRS-1.
- live cirrhosis /
- hepatorenal syndrome /
- diagnosis /
- therapy /
- review

HTML全文

参考文献(32)

[1]YANG L, XING G, WANG L, et al.Acute kidney injury in China:a cross-sectional survey[J].Lancet, 2015, 386 (10002) :1465-1471.

[2]KIM JJ, TSUKAMOTO MM, MATHUR AK, et al.Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis[J].Am J Gastroenterol, 2014, 109 (9) :1436-1442.

[3]GARCIA-TSAO G, PARIKH CR, VIOLA A.Acute kidney injury in cirrhosis[J].Hepatology, 2008, 48 (6) :2064-2077.

[4]HAO KY, YU YC.Several issues regarding evaluation of renal injury and renal insufficiency in patients with liver disease[J].J Clin Hepatol, 2016, 32 (8) :1483-1487. (in Chinese) 郝坤艳, 于乐成.肝病时肾损伤和肾功能不全评估的若干问题[J].临床肝胆病杂志, 2016, 32 (8) :1483-1487.

[5]ZANG H, LIU F, LIU H, et al.Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-onchronic liver failure (ACLF) of underlying cirrhosis[J].Hepato Int, 2016, 10 (5) :807-818.

[6]BITTENCOURT PL, FARIAS AQ, TERRA C.Renal failure in cirrhosis:emerging concepts[J].World J Hepatol, 2015, 7 (21) :2336-2343.

[7]ANGELI P, GINES P, WONG F, et al.Diagnosis and managemen of acute kidney injury in patients with cirrhosis:revised consensus recommendations of the International Club of Ascites[J].Gut, 2015, 62 (4) :968-974.

[8]BAGSHAW SM, UCHINO S, CRUZ D, et al.A comparison of observed versus estimated baseline creatinine for determination of RI-FLE class in patients with acute kidney injury[J].Nephrol Dial Transplant, 2009, 24 (9) :2739-2744.

[9]SHERMAN DS, FISH DN, TEITELBAUM I.Assessing renal function in cirrhotic patients:problems and pitfalls[J].Am J Kidney Dis, 2003, 41 (2) :269-278.

[10]SANYAL AJ, BOYER T, GARCIA-TSAO G, et al.A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J].Gastroenterology, 2008, 134 (5) :1360-1368.

[11]SAGI SV, MITTAL S, KASTURI KS, et al.Terlipressin therapy for reversal of type 1 hepatorenal syndrome:a meta-analysis of randomized controlled trials[J].J Gastroenterol Hepatol, 2010, 25 (5) :880-885.

[12]BOYER TD, SANYAL AJ, WONG F, et al.Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1[J].Gastroenterology, 2016, 150 (7) :1579-1589.

[13]CAVALLIN M, PIANO S, ROMANO A, et al.Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome:a randomized controlled study[J].Hepatology, 2016, 63 (3) :983-992.

[14]SALERNO F, NAVICKIS RJ, WILKES MM.Albumin treatment regimen for type 1 hepatorenal syndrome:a dose-response meta-analysis[J].BMC Gastroenterol, 2015, 15:167.

[15]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[16]EGEROD ISRAELSEN M, GLUUD LL, KRAG A.Acute kidney injury and hepatorenal syndrome in cirrhosis[J].J Gastroenterol Hepatol, 2015, 30 (2) :236-243.

[17]CAVALLIN M, KAMATH PS, MERLI M, et al.Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:a randomized trial[J].Hepatology, 2015, 62 (2) :567-574.

[18]POMIER-LAYRARGUES G, PAQUIN SC, HASSOUN Z, et al.Octreotide in hepatorenal syndrome:a randomized, double-blind, placebo-controlled, crossover study[J].Hepatology, 2003, 38 (1) :238-243.

[19]SRIVASTAVA S, SHALIMAR, VISHNUBHATLA S, et al.Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome[J].J Clin Exp Hepatol, 2015, 5 (4) :276-285.

[20]GOYAL O, SIDHU SS, SEHGAL N, et al.Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1:a prospective, randomized trial[J].J Assoc Physicians India, 2016, 64 (9) :30-35.

[21]NASSAR JUNIOR AP, FARIAS AQ, D'ALBUQUERQUE LA, et al.Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome:a systematic review and meta-analysis[J].PLoSOne, 2014, 9 (9) :e107466.

[22]SHARMA P, KUMAR A, SHRAMA BC, et al.An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response[J].Am J Gastroenterol, 2008, 103 (7) :1689-1697.

[23]DUVOUX C, ZANDITENAS D, HZODE C, et al.Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome:a pilot study[J].Hepatology, 2002, 36 (2) :374-380.

[24]BRENSING KA, TEXTOR J, PERZ J, et al.Long term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome:a phase II study[J].Gut, 2000, 47 (2) :288-295.

[25]WONG F, PANTEA L, SNIDERMAN K.Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1hepatorenal syndrome[J].Hepatology, 2004, 40 (1) :55-64.

[26]BRENSING KA, TEXTOR J, STRUNK H, et al.Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome[J].Lancet, 1997, 349 (9053) :697-698.

[27]CHEN L, MEI Y, YANG YB, et al.Research advances in renal replacement therapy for hepatorenal sydrome[J].J Clin Hepatol, 2016, 32 (2) :605-608. (in Chinese) 陈丽, 梅永, 杨亦彬, 等.肾脏替代疗法治疗肝肾综合征的研究进展[J].临床肝胆病杂志, 2016, 32 (2) :605-608.

[28]MITZNER SR, STANGE J, KLAMMT S, et al.Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS:results of a prospective, randomized, controlled clinical trial[J].Liver Transpl, 2000, 6 (3) :277-286.

[29]ZHANG Z, MADDUKURI G, JAIPAUL N, et al.Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin[J].JCrit Care, 2015, 30 (5) :969-974.

[30]WONG F.Treatment to improve acute kidney injury in cirrhosis[J].Curr Treat Options Gastroenterol, 2015, 13 (2) :235-248.

[31]BOYER TD, SANYAL AJ, GARCIA-TSAO G, et al.Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J].Liver Transpl, 2011, 17 (11) :1328-1332.

[32]LEE JP, KWON HY, PARK JI, et al.Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation[J].Liver Transpl, 2012, 18 (10) :1237-1244.

施引文献

资源附件(0)

访问统计